• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary therapy. >Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study
【24h】

Classification of Patients with COPD on LAMA Monotherapy Using the GOLD Criteria: Analysis of a Claims-Linked Patient Survey Study

机译：使用金标准的喇嘛单药治疗患者的分类：索赔与患者调查研究分析

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionTo address the burden of chronic obstructive pulmonary disease (COPD), the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recommends treatment according to classification of patients by symptom severity and exacerbation risk. This post hoc analysis of a previously reported claims-linked, cross-sectional survey [study 205862 (HO-16-16642)] classified patients with COPD receiving long-acting muscarinic antagonist (LAMA) monotherapy based on the GOLD 2017 categories. MethodsEligible patients who were ≥?40?years of age, with ≥?2 claims with International Classification of Diseases-10th Revision-Clinical Modification COPD diagnosis codes J40–J44 ≥?30?days apart during the 12-month baseline period, and ≥?2 claims for LAMA monotherapy in the 6?months prior to identification, were identified using claims data from the Optum Research Database. Patients completed a survey assessing modified Medical Research Council (mMRC) Dyspnea Scale and COPD Assessment Test (CAT) scores and demographics; clinical characteristics were assessed from claims and survey data, while exacerbation history was assessed from claims data. GOLD symptom severity classifications were low (groups A and C) for patients with low scores on both the CAT and mMRC scales (scores of ResultsOf 433 patients included, 85.5% reported a CAT total score ≥?10, and 45.5% reported mMRC grades 2–4. During the baseline period, 63.7% of patients had ≤?1?moderate and 0 severe (hospitalized) exacerbations, and 36.3% had ≥?1 severe or ≥?2 moderate exacerbation(s). The proportions of patients with each GOLD classification were: A: 9.0%; B: 54.7%; C: 4.6%; D: 31.6%. ConclusionsIn this population, over 85% of LAMA monotherapy users have symptoms and/or exacerbation risk that may necessitate therapy escalation according to 2017 GOLD guidelines. FundingGlaxoSmithKline [study 205862 (HO-16-16642)].
机译：简介解决了慢性阻塞性肺病的负担（COPD），全球慢性阻塞性肺病（金）的倡议（金）建议根据患者的分类进行治疗，症状严重程度和加剧风险。该后HOC分析了先前报道的索赔相关的横截面调查[研究205862（HO-16-16642）]分类患者，接受基于黄金2017类的COPD接受长效毒蕈碱拮抗剂（喇嘛）单药治疗。方法≥20岁的方法，≥2岁，患有国际疾病的索赔 - 第10次修正临床修饰COPD诊断码J40-J44≥？30？几天在12个月的基线期间，≥ ？2在识别前6月6月的达玛单药治疗的权利要求，使用来自Optum Research数据库的索赔数据确定了识别。患者完成了调查评估修改后医学研究委员会（MMRC）呼吸困难和COPD评估试验（CAT）分数和人口统计学;根据索赔和调查数据评估临床特征，同时从索赔数据评估恶化历史。猫和MMRC尺度低分分数的患者的金症状严重程度分类低（A和C）低（A和C）（433名患者的结果，85.5％报告的猫总分≥10分，45.5％报告MMRC等级2 -4。在基线期间，63.7％的患者≤α1？中等和0严重（住院）加剧，36.3％具有≥≤1严重或≥？2中等的恶化的患者的比例黄金分类是：A：9.0％; B：54.7％; C：4.6％; D：31.6％。结论这一人口超过85％的喇嘛单药治疗用户有可能根据2017年的治疗升级症状和/或加剧风险。金指南。FundingGlaxosMithkline [研究205862（HO-16-16642）]。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号